Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations

Long-acting (LA) anti-HIV regimens show promise for increasing dosing intervals and consequently, improving the patients’ quality of life. The first FDA-approved LA therapy is Cabenuva, which comprises rilpivirine (a non-nucleoside reverse transcriptase inhibitor) and cabotegravir (integrase strand...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Maria E. Cilento, Yee Tsuey Ong, Philip R. Tedbury, Stefan G. Sarafianos
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2022-05-01
Serier:	Viruses
Fag:	EFdA islatravir synergy long-acting regimens
Online adgang:	https://www.mdpi.com/1999-4915/14/6/1202
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!